Diane OK means return to French market, as EU OC safety review continues
This article was originally published in SRA
Executive Summary
Now that the European Commission has confirmed that Bayer's acne product, Diane (cyproterone acetate plus ethinylestradiol), should remain on the market but under strict prescribing conditions1, attention will turn to the fate of combined hormonal contraceptives, which are also under scrutiny for their potential to cause thrombotic events.